ArticleProceedings of the National Academy of Sciences of the United States of America2022
CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory.
Open access · greenAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers.
0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed
15.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed, 188 citations in OpenAlex.
- Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade.Cancer discovery · 2025Trial
- Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.Nature medicine · 2024Trial
- Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity.Cancer research · 2026Article
- BLIMP-1 and CD39 expression define human effector memory regulatory T cells in blood and recall responses to viruses.Immunology and cell biology · 2026Article
- Regulatory T cell induction strategies and applications in the treatment of immune and non-immune diseases.Signal transduction and targeted therapy · 2026Review
- Intratumoral Regulatory T-cell Ablation Mediates Tumor Control Systemically without Autoimmunity.Cancer research · 2026Article
- Targeting the αvβ5 Integrin Modifies the TGFβ-Rich Tumor Microenvironment of Pancreatic Cancer.Cancer research · 2026Article
- Epigenetic landscape, key transcriptional regulators, and in vivo identification of human Tr1 cells.Science advances · 2026Article
- Maintenance DNA methylation is necessary for age-related alterations in regulatory T cell transcriptional and DNA methylation signatures.bioRxiv : the preprint server for biology · 2026Article
- CA19-9 induces microenvironment remodeling in pancreatic ductal adenocarcinoma.bioRxiv : the preprint server for biology · 2026Article
- Regulatory T Cells in Hepatocellular Carcinoma: Spatial Niches, Biomarkers, and Clinical Implications.International journal of molecular sciences · 2026Review
- Targeting regulatory T cells in gastrointestinal cancers: current status and future perspectives.International journal of clinical oncology · 2026Review
- Pancreatic ductal adenocarcinoma: integrating molecular insights for targeted interventions.Signal transduction and targeted therapy · 2026Review
- Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies.Molecular cancer · 2026Review
- CCR8The Journal of allergy and clinical immunology · 2026Article
- CAR T cells targeting CCR4 selectively deplete human Tregs ex vivo and in vivo.Blood advances · 2026Article
- CCR8 orchestrates an immunosuppressive niche in the liver to promote Echinococcus multilocularis infection.PLoS neglected tropical diseases · 2026Article
- Specific depletion of TIGITJournal for immunotherapy of cancer · 2026Article
- Coagulation factor V as a novel regulator of tumor immunity in melanoma.World journal of surgical oncology · 2026Article
- Regulatory T Cell Heterogeneity in the Steady State and Tumor.Immune network · 2026Review
64 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors at 2 institutions in 1 country.
Yujiro KidaniDepartment of Basic Research in Tumor Immunology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Wataru NogamiPharmaceutical Research Division, Shionogi & Co., Ltd., 561-0825 Osaka, Japan.
Yoshiaki YasumizuDepartment of Experimental Immunology, Immunology Frontier Research Center, Osaka University, 565-0871 Osaka, Japan.
Atsunari KawashimaDepartment of Urology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Atsushi TanakaDepartment of Basic Research in Tumor Immunology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Yudai SonodaPharmaceutical Research Division, Shionogi & Co., Ltd., 561-0825 Osaka, Japan.
Yumi TonaPharmaceutical Research Division, Shionogi & Co., Ltd., 561-0825 Osaka, Japan.
Kunitaka NashikiPharmaceutical Research Division, Shionogi & Co., Ltd., 561-0825 Osaka, Japan.
Reimi MatsumotoPharmaceutical Research Division, Shionogi & Co., Ltd., 561-0825 Osaka, Japan.
Masaki HagiwaraDepartment of Basic Research in Tumor Immunology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Motonao OsakiDepartment of Experimental Immunology, Immunology Frontier Research Center, Osaka University, 565-0871 Osaka, Japan.
Keiji DohiPharmaceutical Research Division, Shionogi & Co., Ltd., 561-0825 Osaka, Japan.
Takayuki KanazawaPharmaceutical Research Division, Shionogi & Co., Ltd., 561-0825 Osaka, Japan.
Azumi UeyamaPharmaceutical Research Division, Shionogi & Co., Ltd., 561-0825 Osaka, Japan.
Mai YoshikawaPharmaceutical Research Division, Shionogi & Co., Ltd., 561-0825 Osaka, Japan.
Tetsuya YoshidaDepartment of Basic Research in Tumor Immunology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Mitsunobu MatsumotoPharmaceutical Research Division, Shionogi & Co., Ltd., 561-0825 Osaka, Japan.
Kanji HojoPharmaceutical Research Division, Shionogi & Co., Ltd., 561-0825 Osaka, Japan.
Satomi ShinonomePharmaceutical Research Division, Shionogi & Co., Ltd., 561-0825 Osaka, Japan.
Hiroshi YoshidaPharmaceutical Research Division, Shionogi & Co., Ltd., 561-0825 Osaka, Japan.
Michinari HirataPharmaceutical Research Division, Shionogi & Co., Ltd., 561-0825 Osaka, Japan.
Miya HarunaPharmaceutical Research Division, Shionogi & Co., Ltd., 561-0825 Osaka, Japan.
Yamami NakamuraDepartment of Experimental Immunology, Immunology Frontier Research Center, Osaka University, 565-0871 Osaka, Japan.
Daisuke MotookaGenome Information Research Center, Research Institute for Microbial Diseases, Osaka University, 565-0871 Osaka, Japan.
Daisuke OkuzakiGenome Information Research Center, Research Institute for Microbial Diseases, Osaka University, 565-0871 Osaka, Japan.
Yasuko SugiyamaDepartment of Neurology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Makoto KinoshitaDepartment of Neurology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.ORCID 0000-0001-7012-6782
Tatsusada OkunoDepartment of Neurology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Taigo KatoDepartment of Urology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Koji HatanoDepartment of Urology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Motohide UemuraDepartment of Urology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Ryoichi ImamuraDepartment of Urology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Kazunori YokoiDepartment of Dermatology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Atsushi TanemuraDepartment of Dermatology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Yasushi ShintaniDepartment of General Thoracic Surgery, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Tadashi KimuraDepartment of Obstetrics and Gynecology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Norio NonomuraDepartment of Urology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Hisashi WadaDepartment of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Masaki MoriDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Yuichiro DokiDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan.
Naganari OhkuraDepartment of Basic Research in Tumor Immunology, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan; nohkura@ifrec.osaka-u.ac.jp shimon@ifrec.osaka-u.ac.jp.
Shimon SakaguchiDepartment of Experimental Immunology, Immunology Frontier Research Center, Osaka University, 565-0871 Osaka, Japan; nohkura@ifrec.osaka-u.ac.jp shimon@ifrec.osaka-u.ac.jp.
The University of Osaka · JPShionogi (Japan) · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foxp3-expressing CD25
Indexed as
Immunologic MemoryAnimalsAntibodies, MonoclonalBiomarkers, TumorCell- and Tissue-Based TherapyCell DifferentiationForkhead Transcription FactorsGene DeletionGene Expression Regulation, NeoplasticHumansMiceNeoplasmsReceptors, CCR8T-Lymphocytes, RegulatoryAntibodies, MonoclonalBiomarkers, TumorCCR8 protein, humanCcr8 protein, mouseForkhead Transcription FactorsFoxp3 protein, mouseReceptors, CCR8autoimmunitycancer immunotherapyCCR8regulatory T cellsTCR repertoire
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.